Ellipse Pharmaceuticals

ELLIPSE Pharmaceuticals is providing state-of-the-art Pharmaceutical Development services.
ELLIPSE is working on the development of original drug delivery systems & new therapeutic systems which are patended & available for licensing.
ELLIPSE services include: Formulation Development, Industrial Transfer, Analytical Development & Validation,
ICH stability studies, Regulatory Affairs.

Activity:

- Licensing & Business Development
- Regulatory Affairs & Legal Services
- Research & Development

Product / Technology type(s) covered:

- Drug delivery
- Generics
- FP (finished products)
- NCE (new chemical entities)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Phyto
- Nutritionals / Vitamins
- Prescription drugs (Rx)
- Proteins

Therapeutic targets:

- Aging
- AIDS
- Allergy
- Alzheimer's Disease
- Arthritis / Rheumato
- Asthma
- Cancer
- Cardiovascular
- Central nervous system
- Cough / Cold
- Dermatology
- Diabetes
- Epidemiology
- Gastrointestinal
- Genetics
- Geriatrics
- Hematology
- Infectious Diseases
- Men's Health
- Mental Health
- Neurology
- Obesity
- Oncology
- Ophthalmology
- Orthopedics
- Pain
- Pediatrics
- Radiology
- Reproductive Health
- Respiratory Medicine
- Stroke
- Surgery
- Tonics
- Transplant
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: France

b. Continent(s) active: Europe , Near/Middle East

c. Countries active: Europe

Corporate data:

Number of Employees: 20

Turnover:

Amount:	Year:	Currency:
2 000 000	2006	Euro

Year founded: 1999

Partners / Alliances: Member of BERTIN Group (420 people, 40 millions €)